Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer
November 05, 2024 09:01 ET
|
Nouscom Srl
Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well...
Nouscom to Present Updated Positive Data on NOUS-209’s Potential to ‘Intercept’ Cancer in Lynch Syndrome Carriers at SITC 2024
October 04, 2024 09:00 ET
|
Nouscom Srl
BASEL, Switzerland – 4th October 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announces...
Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development
July 17, 2024 03:00 ET
|
Nouscom Srl
BASEL, Switzerland – 17th July 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today...
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
May 14, 2024 03:00 ET
|
Nouscom Srl
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that...
Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round
November 14, 2023 01:00 ET
|
Nouscom Srl
New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key...
Nouscom’s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to ‘Intercept’ Cancer in Subjects with Lynch Syndrome
October 31, 2023 09:01 ET
|
Nouscom Srl
Lynch Syndrome is a common hereditary condition associated with a genetic predisposition to and high-risk of developing colorectal and other cancersPhase 1b trial evaluating NOUS-209 monotherapy in...
Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023
April 18, 2023 03:00 ET
|
Nouscom Srl
NOUS-PEV demonstrated good safety and immunogenicity, and induced durable neoantigen-specific T cell responses that were detected for over 6 months and increased T cell infiltration in tumors...
Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy
March 15, 2023 04:00 ET
|
Nouscom Srl
BASEL, Switzerland – 15th March 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new translational...